Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    HomeNewsBusinessStocksBuy Aurobindo Pharma; target of Rs 965: ICICI Direct

    Buy Aurobindo Pharma; target of Rs 965: ICICI Direct

    ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 965 in its research report dated February 13, 2017.

    February 13, 2017 / 17:02 IST
       
       
      26 Aug, 2025 12:21
      Volume
      Todays L/H
      More
      ICICI Direct's research report onAurobindo Pharma
      After filing its first ANDA in the US in 2003, the company has come a long way as the current ANDA filings are at 421. The US revenue run rate has grown from US$100 million in FY09 to US$935 million as on FY16. Note that this was despite the USFDA embargo in FY12-13 on unit VI and unit III.
      Outlook
      We believe launches continuum, especially in the injectable space, can effectively neutralised channel consolidation and pricing pressure headwinds. Other important segment i.e. Europe is likely to fetch better margins on the back of product transfers to India and focussed approach. We have ascribed a target price of Rs 965, based on 19x (earlier 20x) FY19E EPS of Rs 50.7.
      For all recommendations, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

      Read More Read More

      first published: Feb 13, 2017 05:02 pm

      Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

      Subscribe to Tech Newsletters

      • On Saturdays

        Find the best of Al News in one place, specially curated for you every weekend.

      • Daily-Weekdays

        Stay on top of the latest tech trends and biggest startup news.

      Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347